SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Far below the surface, where light no longer reaches and noise collapses into silence, the Sperm Whale endures.  It does not rely on speed or spectacle. It survives through mass, intelligence, and absolute awareness of its surroundings.  This project is shaped by the same principle — strength formed under pressure, movement guided by understanding, and conviction built where others cannot remain.  While the surface reacts, the deep decides.

The Sperm Whale

Sperm Whale is currently trending as a highly speculative meme coin on Solana, driving intense debate between participants chasing rapid, high-percentage gains and skeptics warning of potential pump-and-dump mechanics. Community sentiment is deeply polarized, with some bullish traders highlighting the project's chart structure and whale-driven price action, while others caution that the lack of fundamental utility and high concentration among top holders signal a significant risk.

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

VCX is trending as retail traders scramble for exposure to AI leaders like OpenAI, Anthropic, and SpaceX, fueling a meme-like frenzy that has sent the stock soaring despite warnings of extreme overvaluation relative to its net asset value. Community members are actively debating the sustainability of this parabolic run, with many highlighting that the limited tradable float due to lockup periods is creating intense volatility and aggressive short-squeeze dynamics.

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.

Terns Pharmaceuticals Inc

Terns Pharmaceuticals is capturing significant investor attention following promising Phase 1 clinical data for its leukemia candidate, TERN-701, which has sparked intense debate over the company's valuation and potential as an acquisition target. The community is deeply divided between bulls citing the drug's best-in-disease profile and analysts raising price targets, while bears express skepticism about the sustainability of the current valuation and the potential for near-term dilutive share offerings.

Destiny Tech100, Inc. operates as a non-diversified, closed-end management investment company. The company was founded on November 18, 2020 and is headquartered in Austin, TX.

Destiny Tech100 Inc

DESTINY TECH 100 INC

Destiny Tech 100 is capturing significant retail interest driven by its concentrated exposure to private tech leaders like SpaceX and Anthropic, which investors are tracking closely ahead of potential IPO activity. The community is actively debating the stock's substantial premium to its net asset value, with traders comparing its valuation mechanics to other proxy investment funds in the sector.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

Circle ($CRCL) is experiencing significant volatility following a leaked draft of the Clarity Act, which proposes banning stablecoin yield-sharing models and has sparked intense debate over the long-term viability of the company's revenue model. While some retail investors are buying the dip and betting on Circles role as a future payment utility, others remain skeptical, pointing to aggressive insider selling and ongoing regulatory uncertainty as signs of an overvalued asset.

Personalis, Inc. engages in the provision of advanced genomic tests for cancer. The firm is also involved in providing sequencing and data analysis services to support population sequencing initiatives. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in February 2011 and is headquartered in Fremont, CA.

Personalis Inc

Personalis is trending as investors focus on recent positive updates regarding Medicare coverage prospects and the company's strong clinical test volume growth, which is being driven by its pivotal role in the precision oncology ecosystem alongside Tempus. The community is actively debating the company's long-term potential as a 'picks and shovels' leader in cancer diagnostics, closely monitoring upcoming earnings and the timing of regulatory milestones that could trigger a significant re-rating of the stock.

Axon Enterprise, Inc. engages in the development, manufacture, and sale of conducted electrical weapons for personal defense. It operates through the TASER segment and Software and Sensors segment. The TASER segment sells conducted electrical weapons, accessories, and other related products and services. The Software and Sensors segment includes devices, wearables, applications, cloud, and mobile products. The company was founded by Patrick W. Smith and Thomas P. Smith on September 7, 1993 and is headquartered in Scottsdale, AZ.

Axon Enterprise Inc

Axon is experiencing significant volatility as investors digest broader software sector weakness, leading to a sharp multi-day selloff despite stable fundamental demand and potential catalysts from federal body camera mandates. The community remains deeply divided, with many long-term shareholders holding through the drawdown while actively discussing the impact of insider selling, valuation concerns, and the stock's tendency to undergo steep corrections before recovery.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is facing significant selling pressure as investors grapple with concerns over the company's heavy AI-related capital expenditure and potential competitive headwinds in the enterprise software space. The community remains deeply polarized, with many buyers viewing the current valuation as a generational entry point, while others argue that the stock's persistent downtrend signals deeper structural weakness that demands further patience.

FuboTV, Inc. is a consumer-first live TV streaming company with the mission of delivering premium sports, news and entertainment programming that offers greater choice, flexibility and value. The company was founded by David Gandler, Alberto Horihuela Suarez, and Sung Ho Choi on February 20, 2009 and is headquartered in New York, NY.

fuboTV Inc - Ordinary Shares - Class A

fuboTV Inc

FuboTV investors are currently fixated on the company's approved 1-for-12 reverse stock split, which has sparked intense debate regarding potential dilution and the stock's long-term valuation. Community sentiment is deeply polarized between long-term holders frustrated by management's silence and the lack of major sports content, and speculative traders looking for volatility catalysts amidst low liquidity.

Eastman Kodak Co. engages in the provision of analog and digital innovations. It operates through the following segments: Traditional Printing, Digital Printing, Advanced Materials and Chemicals, and Brand. The Traditional Printing segment consists of Prepress Solutions, which includes Kodak's digital offset plate offerings and computer-to-plate imaging solutions. The Digital Printing segment contains Electrophotographic Printing Solutions, Prosper, Versamark and Software. The Advanced Materials and Chemicals segment consists of four lines of business: Industrial Film and Chemicals, Motion Picture, Advanced Materials and Functional Printing, and Kodak Services for Business (KSB). The Brand segment includes licensing of the Kodak brand to third parties. The company was founded by George Eastman in 1880 and is headquartered in Rochester, NY.

Eastman Kodak Co.

Eastman Kodak is trending as investors focus on its pivot into pharmaceutical API manufacturing and advanced battery materials, with ongoing discussions surrounding potential government contracts and the company's asset-rich balance sheet. The community is actively debating the stock's valuation, often highlighting the significant gap between current market pricing and the underlying value of its extensive real estate and legacy manufacturing capabilities.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

LeMaitre Vascular, Inc. $LMAT Shares Acquired by Congress Asset Management Co.

Congress Asset Management Co. boosted its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 5.8% during the fourth quarter, according to its most recent 13F filing with the SEC. The...

LeMaitre Vascular (NASDAQ:LMAT) Stock Passes Above 200-Day Moving Average - What's Next?

LeMaitre Vascular (NASDAQ:LMAT) Share Price Passes Above 200-Day Moving Average - Here's What Happened...

Kennedy Capital Management LLC Has $18.89 Million Holdings in LeMaitre Vascular, Inc. $LMAT

Kennedy Capital Management LLC raised its position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 31.6% in the third quarter, according to its most recent 13F filing with the...

LeMaitre Vascular, Inc. (NASDAQ:LMAT) Announces Quarterly Dividend of $0.25

LeMaitre Vascular, Inc. (NASDAQ:LMAT) declared a quarterly dividend on Thursday, February 19th. Stockholders of record on Thursday, March 12th will be given a dividend of 0.25 per share by the...

First Trust Advisors LP Grows Stock Holdings in LeMaitre Vascular, Inc. $LMAT

First Trust Advisors LP boosted its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 35.4% during the 3rd quarter, according to its most recent 13F filing with the Securities...

LeMaitre Vascular, Inc. $LMAT Shares Sold by JPMorgan Chase & Co.

JPMorgan Chase & Co. reduced its position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 18.6% during the third quarter, according to the company in its most recent Form 13F...

LeMaitre Vascular, Inc. (NASDAQ:LMAT) Receives Average Rating of "Hold" from Analysts

LeMaitre Vascular, Inc. (NASDAQ:LMAT - Get Free Report) has been assigned a consensus rating of "Hold" from the seven ratings firms that are presently covering the firm, MarketBeat reports. Four...

LeMaitre Vascular (NASDAQ:LMAT) Insider Sells $115,142.76 in Stock

LeMaitre Vascular, Inc. (NASDAQ:LMAT - Get Free Report) insider Trent Kamke sold 1,044 shares of the company's stock in a transaction dated Friday, February 27th. The shares were sold at an average...

LeMaitre Vascular (NASDAQ:LMAT) Director Sells $903,955.20 in Stock

LeMaitre Vascular, Inc. (NASDAQ:LMAT - Get Free Report) Director David Roberts sold 8,464 shares of the business's stock in a transaction that occurred on Friday, February 27th. The stock was sold at...

LeMaitre Vascular (NASDAQ:LMAT) CEO Sells $16,014,000.00 in Stock

LeMaitre Vascular, Inc. (NASDAQ:LMAT - Get Free Report) CEO George Lemaitre sold 150,000 shares of the company's stock in a transaction on Thursday, February 26th. The stock was sold at an average...

LeMaitre Vascular, Inc. engages in the provision of medical devices and human tissue cryopreservation services. The company focuses on the design, marketing, sales, service, and technical support of medical devices and implants for the treatment of peripheral vascular disease. Its products include balloon catheters, carotid shunts, biologic patches, radiopaque marking tape, anastomotic clips, remote endarterectomy devices, laparoscopic cholecystectomy devices, vascular grafts, and powered phlebectomy. The company was founded by George D. LeMaitre on November 28, 1983 and is headquartered in Burlington, MA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	$0.66	--	--	N/A
Q4 '25	$0.66	$0.68	2.37%	BEAT
Q3 '25	$0.57	$0.75	32.57%	BEAT
Q2 '25	$0.57	$0.60	5.88%	BEAT
Q1 '25	$0.50	$0.48	-3.65%	MISSED

LMAT
Lemaitre Vascular Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q1 '26

Historical Earnings

Latest LMAT News

LMATLemaitre Vascular Inc